Clinical Study of Pediatric Acute Liver Failure
A Prospective Study on the Real Word of Acute Liver Failure in Children
1 other identifier
observational
7
1 country
1
Brief Summary
The goal of this observational study is to understand the etiology, prognosis and influencing factors of acute liver failure in children, evaluate the predictive value of children's SOFA score, PELD score and LIU score for the short-term mortality rate of children's liver failure and the infection of children's acute liver failure; analyze the bleeding and kidney damage of children's acute liver failure, and evaluate the quality of life of children's acute liver failure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2024
CompletedFirst Submitted
Initial submission to the registry
March 18, 2025
CompletedFirst Posted
Study publicly available on registry
March 25, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2026
March 25, 2025
August 1, 2024
1.9 years
March 18, 2025
March 18, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
With the changes of various indicators such as blood ammonia albumin lactic acid coagulation function with the implementation of treatment
All are specific numerical measurements.
From enrollment to the end of treatment at 6 months
Eligibility Criteria
The children under the age of 18 diagnosed with acute liver failure in Guangzhou Women's and Children's Medical Center.
You may qualify if:
- (1) The age is less than 18 years old; (2) Acute onset (≤8 weeks), no liver disease basis in the past; (3) Biochemical evidence of severe liver injury ; (4) Coagulation dysfunction that cannot be corrected by vitamin K: prothrombin time (PT) ≥15s or international standardized ratio (INR) ≥1.5, and accompanied by hepatic encephalopathy at the same time; or meet any of PT≥20s, INR≥2.0, may not be accompanied by hepatic encephalopathy; (5) Provide complete clinical data and treatment records. (6) Agree to participate in this study and obtain informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fansen Zenglead
Study Sites (1)
Guangzhou Women's and Children's Medical Center
Guangzhou, Guangdong, 510000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- associate chief physician
Study Record Dates
First Submitted
March 18, 2025
First Posted
March 25, 2025
Study Start
September 1, 2024
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
August 1, 2026
Last Updated
March 25, 2025
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- 2026/09/01-2031/09/01
all IPD that underlie results in a publication